PolyPeptide Group is launching a new product line for the global market.
Published
Signal category
Strategy & Corporate Development
Quote
“PolyPeptide Group is launching a new product line for the global market”
— Sochan Rumthao, Ph.D.|PolyPeptide Group team
Company
PolyPeptide Group
Contract Development & Manufacturing Organization (CDMO) for peptide-based APIs.
- Industry
- Pharmaceutical Manufacturing
- Location
- Baar, CH
- Company size
- 1,475 employees
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/
Founded 1996